

REFERENCE

=====

Ahern, C.P. (1986):

Halothane dose response in malignant hyperthermia swine.
International workshop on malignant hyperthermia, Leeds.

**Allen, P.D.; Ryan, J.F.; Jones, D.E.; Mabuchi, K.; Virga, A.;
Roberts, J. and Sreter, F. (1986):**

Sarcoplasmic reticulum calcium uptake in cryostat
sections of skeletal muscle from malignant hyperthermia
patients and controls.
Muscle and nerves 9: 474-475.

**Amaranath, L.; Lavin, T.J.; Trusso, R.A. and Boutras, A.R.
(1983):**

Evaluation of creatinine phosphokinase screening as a
predictor of malignant hyperthermia. A prospective
study.
Br. J. of Anaesth. 55: 531-533.

**Baudendistel, L.; Goudsouzian, N.; Cote, C. and Strafford,
M. (1984):**

End-tidal CO₂ monitoring.
Anaesthesia 39: 1000-1003.

Benca, J.F. and Rockoff, M.A. (1988):

Malignant hyperthermia.
Adv. Anaesthesia 5:237-260.

Bennet, M.H. and Wainwright, A.P. (1989):

Acute thyroid crisis on induction of anaesthesia.
Anaesthesia 44: 28-30.

Beverly, A. and Britt, M. (1985):

Malignant hyperthermia.
Can Anaesth. Soc. J. 132(6): 666-677.

Blank, T.J.J.; Fisher, Y.I.; Thompson, M. and Maldoon, S. (1984):

Low molecular weight proteins in human malignant hyperthermic muscle.
Anaesthesiology 61: 589-592.

Bohler, J. and Eger, E.I. (1982):

Isoflurane and malignant hyperthermia.
Ansth. Analg. 61: 712-714.

Brownell, A.K.W. (1988):

Malignant hyperthermia: Relationship to other diseases.
B. J. Anaesthesia 60: 303-308.

Brownell, A.K.W.; Paasuke, R.T.; Elush, A.; Fowlow, S.B.; Seagram, C.G.F.; Diwold, R.J. and Friesen, C. (1985):

Malignant hyperthermia in Duchenne Muscular Dystrophy.
Anaesthesiology, 58: 180-182.

Britt, B.A. and Scott, E.A. (1986):

Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
Anaesth. and Analgesia 65: 171-175.

Britt, B.A.; Scott, E.A.; Kleiman, A.; Jones, P. and Steward, D.J. (1986):

Failure of the tourniquet-twitch test as a diagnostic or screening test for malignant hyperthermia.
Anaesthesia and Analgesia 65: 1047-1050.

Britt, B.A. (1984):

Dantrolene-a review.
Can. Anaesth. Soc. J. 31: 61-75.

Britt, B.A. (1976):

Malignant hyperthermia.
Modern Medicine of Canada, June.

Britt, B.A.; Endrenyi, L.; Kalow, W. and Peters, P.L. (1976):

The adenosine triphosphate (ATP) depletion test: comparison with the caffeine contracture test as a method of diagnosing malignant hyperthermia susceptibility.
Canadian Anaesthetists Society J. 23: 624-635.

Britt, B.A.; Endrenyi, L. and Peters, P.L. (1976):

Screening of malignant hyperthermic susceptible families by CRK. measurement and other clinical investigations.
Can. Anaesth. Soc. J. 23: 263.

Crider, B.; Nightengale, P. and Hill, A. (1986):

Intraoperative hyperpyrexia: Keep an open mind
Anaesthesiology 64: 413.

Denborough, M.A.; Galloway, G.J. and Hopkinson, K.C. (1982):

Malignant hyperthermia and sudden infant death.
Lancet 2: 1068-1069.

Denborough, M. and Lovell, R. (1960):

Anaesthetic death in a family.
Lancet 2: 45.

Dershwitz, M.; Sreter, F.A. and Ryan, J.F. (1989):

Ketamine does not trigger malignant hyperthermia in susceptible swine.
Anaesth. Analgesia 69: 501-503.

Dunn, C.M.; Maltry, D.E. and Eggers, G.W.N.J.R. (1985):

Value of mass spectrometry in early diagnosis of malignant hyperthermia.
Anaesthesiology 63: 333.

Edelstein, G. and Hishman, C.A. (1980):

Hyperthermia and ketoacidosis during anaesthesia in a child with glycogen storage disease.
Anaesthesiology 52: 90-92.

Eldar, I.; Goldberg, G.; Glauber, V. and Perel, A. (1991):

In vitro diagnosis of malignant hyperpyrexia syndrom.
Harefuah; 15; 121(12): 499-502.

Ellis, F.R. and Halsall, P.J. (1990):

The value of clinical predictors of malignant
hyperthermia susceptible.
J. Neural Sci. 98(suppl. 10): 525.

Ellis, F.R. and Halsall, P.S. (1984):

Suxamethonium spasm.
Br. J. Anaesth. 56: 381-383.

Ellis, F.R.; Halsall, P.J.; Allam, P. and Hay, E. (1984):

A biochemical abnormality susceptible humans.
Biochemical socety trans actions 12: 357-358.

**Ellis, F.R.; Drake, J.D.; Halsall, P.J.; Hay, E. and
Campbell, I.J. (1982):**

Increased glycolysis of muscle in unstressed patiens
susceptible to malignant hyperthermia.
Br. J. Anaes. 54: 1132-1133.

Ellis, F.R. (1981):

Malignant hyperpyrexia, in Ellis F.R. (ed.): Inherited
Disease and anaesthesia.
New York elsevier North-Holland, Inc, P.P. 163-199.

**Ellis, F.R.; Cain, P.A.; Harrisman, D.G.F. and Toothill, C.
(1978):**

Plasma cholinesterase and malignant hyperthermia.
Br. J. of Anaesth. 50: 86.

Eng, G.D.; Becker, M.J. and Muldoon, S.M. (1984):

Electrodiagnostic tests in the detection of malignant
hyperthermia.
Muscle and Nerve; 7: 618-625.

European Malignant Hyperpyrexia Group :

A protocol for the investigation of malignant hyperthermia susceptibility.
Br. J. Anaesth. 46: 1267-1269.

Evans, R.; Iqbal, J.; Ellis, F.R.; Halsall, P.J.; Dietz, A.A.; Lubrano, T. and Rubinstein, H.M. (1981):

Collaborative study of the frequency of the fluorideresistant cholinesterase variant in patients with malignant hyperthermia.
Br. J. Anaesth, 53: 245-247.

Ezri, T. and Soroker, D. (1991):

Pheochromocytoma presending as malignant hyperthermia
Can. J. Anaesth. Jul.; 385(5): 685.

Fishbein, W.N.; Muldoon, S.M.; Deuster, P.A. and Armbrustmacher, V.W. (1985):

Myoadenylate deaminase deficiency and malignant hyperthermia susceptibility : Is there a relationship?
Biochemical Medicine 34: 344-354.

Fletcher, J.E.; Tripolitis, L. and Erwin, K. (1990):

Defects attributed to the Ca^{2+} release channel protein (CRCP) in malignant hyperthermia are consequences of elevated free fatty acids (FFA), and breed differences.
J. Neural Sci. 98 (suppl, 10): 508.

Flewellen, E.F. and Nelson, T.E. (1983):

Is theophylline, aminophylline or caffeine
(methylxanthines) contraindicated in malignant
hyperthermia susceptible patients?
Anaesth. Analg. 62: 115-118.

Flewellen, E.H. and Nelson, T.E. (1980):

Dantrolene dose response in malignant hyperthermia
susceptible swine:
Method of obtain prophylaxis and therapeutics.
Anaesthesiology 52: 303-308.

Gallant, E.M. and Lentz, L.R. (1992):

Excitation-contraction coupling in pigs heterozygous for malignant hyperthermia.
Am. J. Physiol: Feb; 262: PC 422-426.

Gallen, J.S. (1991):

Propofal does not trigger malignant hyperthermia.
Anaesth. Anal. 72: 406-416.

Ganong, W.F. (1989):

Medical physiology.

Gerrard, J.M.; Duncan, P.G.; Kashyk, S.A.; Gloven, S.M. and McCrea, J.M. (1983):

Halothane stimulates the aggregation of platelets of both normal individuals and those susceptible to malignant hyperthermia.
Br. J. of Anaesthesia, 55: 1249-1257.

Gordon, A.S.; Britt, B.A. and Pritzker, K.P.H. (1986):

Myotonia and malignant hyperpyrexia.
Muscle and Nerve; 5 (suppl.) 221.

Gronert, G.A.; Shulman, S.R. and Mott, J. (1990):

Malignant hyperthermia. In: Miller R.D. (Ed.).
Anesthesia 3rd ed., Churchill Livingstone Inc. 950-951.

Gronert, G.; Ahem, C.; Milde, J.H. and White, R.D. (1986):

Effect of CO₂, calcium, digoxin and potassium on cardiac and skeletal muscle metabolism in malignant hyperthermia susceptible swine.
Anaesthesiology 64: 24-28.

Groner, G.A. (1983):

Controversies in malignant hyperthermia.
Anaesthesiology 59: 273-274.

Gronert, G.A. (1980):

Contracture response and energy stores in quadriceps muscle from human age 7-82 years.
Human Biology, 52: 43-51.

Guze, B. and Baxter, L. (1985):

Neuroleptic malignant syndrome.
N. Engl. J. Med. 313: 163-166.

Hackl, W.; Mauritz, W.; Schemper, M.; Winkler, M. Sporn, P. and Steinbruthner, K. (1990):

Prediction of malignant hyperthermia susceptibility; statistical evaluation of clinical signs.
Br. J. Anaesth. 64: 425-429.

Hanel, H.K.; Viby-Mogensen, J. and Schaffalitzky de Muchadell, O.B. (1978):

Serum cholinesterase variants in the Danish population.
Acta anaesthesiology scandinavica 22: 505-507.

Harriman, D.G.F. (1986):

The differentiation of normal muscle and of malignant hyperthermic myopathy, and the association of myopathies with the malignant hyperthermia trait.
Muscle and Nerve 5(supple.): 222.

Harrison, G.G.; Saunders, S.J.; Biebuyek, J.F.; Hickman, R.; Dent, D.M.; Weaver, V. and Terblanche, J. (1969):

Anaesthetic-induced malignant hyperthermia and a method for its prediction.
Br. J. Anaesth. 41: 844-855.

Haytens, L.; Martin, J.J. Van, Dekelet, E. and Bossaert, L.L. (1992):

In vitro contracture tests in patients with various Neuromuscular disease.
B. J. Anaesth. 68: 72-75.

Hogan, K.; Valdivia, H.H. and Coronado, R. (1990):

Ryanodine receptors of human, rabbit and pig skeletal muscle: Differential sensitivity to calcium and Halothane.
J. Neural. Sci. 98; (suppl. 10): 197.

John, F. and Ryan, M.D. (1991):

Malignant hyperthermia and after care New developments in pediatric anaesthesia.
Anaesthesiology clinics of North America 9(4): 913-927.

Jones, D.J. and Breadly, L.L. (1986):

Evaluation of simplified chemiluminescent blood test in malignant hyperthermia, susceptible pigs.
Anaesthesiology 65: A 240.

Joseph, M.M.; Shahk and Viljion, J.F. (1982):

Malignant hyperthermia associated with isoflurane anaesthesia.
Anaesth. Analges. 61: 711-712.

Kalow, W.; Britt, B.A. and Richter, A. (1976):

Individuality in human skeletal muscle as revealed by studies on malignant hyperthermia.
Can. J. Genet. Cytol. 18: 565.

Karpati, G.; Charuk, J.; Carpenter, S.; Jablecki, C. and Holland, P. (1986):

Myopathy caused by a deficiency of Ca^{2+} adenosine triphosphatase in sarcoplasmic reticulum (Brody's disease).
Annals of Neurology 20: 38-49.

Kausch, K.; Lehmann-Horn, F.; Janka, M.; Wieringa, B.; Grimm, T. and Muller, C.R. (1991):

Evidence for linkage of the central core disease locus to the proximal long arm of human chromosome 19.
Genomics 10(3): 765-769.

Kelemen, J.; Rice, M.D.; Munsate, T.Z.; Dimauro, S. and Hogan, E.L. (1982):

Familial myoadenylate deaminase deficiency and exertional myalgia.
Neurology 32: 857-863.

Kiel, J.L. and Erwin, D.N. (1984):

Thermochemiluminescent assay of porcine, rat and human erythrocytes for antioxidative deficiencies.
Analytical Biochemistry 143:231-236.

Kikuchi, H.; Morio, M.; Shinozaki, M. and Ishihara, S. (1982):

Statistical considerations of malignant hyperthermia in Japan in: Aldret J.A.; Britt, B.A. eds. Second international symposium on malignant hyperthermia.
New York: Grune and Stratton 483-498.

King, J.O. and Denborough, M.A. (1973):

Anaesthetic-induced malignant hyperpyrexia in children.
J. of Pediatrics 83: 37-40.

Klip, A.; Ramlal, T.; Walker, D.; Britt, B.A. and Elliott, M.E. (1987):

Selective increase in cytoplasmic calcium by anaesthetic in lymphocytes from malignant hyperthermia susceptible pigs.
Anaesth. and Analg. 66: 381-385.

Kolb, M.E.; Horne, M.L. and Mortz, R. (1982):

Dantrolene in human malignant hyperthermia: A multicenter study.
Anaesthesiology 56: 254-262.

Krivosic-Horber, R. and Krivosic, I. (1989):

Susceptibility to malignant hyperthermia associated with central core disease.
La presse Medicale 18: 828-831.

Larach, M.G. (1989):

For the North American malignant standardization of the
caffeine halothane muscle contracture test.
Anaesth. analg. 69: 511-515.

Lee, M.B.; Adragna, M.G. and Edwards, L. :

The use of a platelet nucleotide essay as a possible
diagnostic test for malignant hyperthermia.

Leeds, D.E.; Giadde, P.L. and Macnamara, T.E. (1980):

Malignant hyperthermia in associated with Burkitt's
lymphoma: report of a third case.
Anaesth. and Analg. 59, 514-515.

Lennmarken, C.; Rutberg, H. and Henriksson, K.G. (1987):

Abnormal relaxation rates in subjects susceptible to
malignant hyperthermia.
Acta Neurologica Scandinavica 75: 81-83.

Lerman, J.; McLeod, M.E. and Strong, H.A. (1989):

Pharmacokinetics of intravenous dantrolene in children.
Anaesthesiology 70: 625-629.

Lerman, J. (1988):

Contraversies in pediatric anaesthesia.
Can. J. Anaesth. 35: 518-522.

**Levitt, R.C.; Meyers, D.; Fletcher, J.E. and Rosenberg, H.
(1991):**

Molecular genetics and malignant hyperthermia.
(Editorial).
Anaesthesiology 73: 1-3.

Lips, F.J.; Newland, M. and Dutton, G. (1982):

Malignant hyperthermia triggered by cyclopropane during
caesarean section.
Anaesthesiology 56: 144-146.

Littleford, J.A.; Patel, L.R.; Base, D.; Cameron, C.B. and McKillop, G. (1991):

Masseter muscle spasm in children implications of continuing the triggering anaesthetic.
Anaesth Analg. 72: 151-160.

Lopez, J.R.; Alam, O.L.; Caputo, C.; Wikinski, J. and Ledezam, D. (1985):

Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia.
Muscle and Nerve, 8: 355-358.

MacGillivray, R.G.; Jann, H.; Vanker, E.; Gemmet, L. and Mahomedy, A.E. (1986):

Development of malignant hyperthermia obscured by cardiopulmonary bypass.
Can. Anaesth. Soc. J. 33: 509-514.

MacKenzie, A.E.; Allen, G. and Lahey, D. (1991):

A comparison of caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia.
Anaesthesiology 73: 4-8.

Marjanen, L.A. and Denborough, M.A. (1982):

Adenylate kinase and malignant hyperpyrexia.
Br. J. of Anaesth. 54: 949-952.

Mathieu, A.; Bogosian, A.J. and Ryan, J.F. (1979):

Recrudescence after survival of an initial episode of malignant hyperthermia.
Anaesthesiology 51: 454-455.

Melton, A.T.; Martucci, R.W.; Kien, N.D. and Gronert, G.A. (1989):

Malignant hyperthermia in humans, standardization of contracture testing protocol.
Anaesth. Analg. 69: 437-443.

McCarthy, T.V. (1990):

Localization of the malignant hyperthermia locus to human chromosomes 19, 12-13.2.
Nature 343: 562-564.

McGraw, T.T. and Keon, T.P. (1989):

Malignant hyperthermia and the clean machine.
Can. J. Anaesth. 36: 530-532.

McPherson, E.W. and Taylor, C.A. (1981):

The king syndrome malignant hyperthermia, myopathy and multiple anomalies.
American Journal of Medical genetics 8: 159-165.

Mitsumoto, N.G.T.C.; Majors, A.W.; Crure, R.P.; Deboer, G.E. and Chou, S.M. (1986):

P-Magnetic resonance spectroscopy (MRs) in malignant hyperthermia.
4th International malignant hyperpyrexia workshop.
New York (Abstract).

Moore, D. (1986):

Ester or amide local anaesthetics in malignant hyperthermia who knows?
anaesthesiology 64: 294-296.

Nelson, T.E.; Fill, M. and Stefani, E. (1990):

Malignant hyperthermia: Single Ca^{2+} release channels in human sarcoplasmic reticulum membranes isolated from biopsied skeletal muscle.
Neurol, Sci. 98(suppl. 10): 5-7.

Ohnishi, S.T. and Katsuoka, M. (1991):

Why does halothane relax cardiac muscle but contract malignant hyperthermic skeletal muscle.
Adv.Exp. Med. Biol; 301: 73-87.

Ohtani, Y.; Milke, T.; Ishitsu, Matsuda, I. and Tamari, H.
(1985):

A case of malignant hyperthermia with mitochondrial dysfunction.
Brain and development 7: 249.

Ono, K.; Topel, D.G.; Christian, L.L. and Althen, T.G.
(1977a):

Relationship of cyclic AMP and phosphorylase a in stress-susceptible and control pigs.
J. of food Science 42: 108-110.

Ono, K.; Topel, D.G. and Althen, T.G. (1977b):

Adenylate cyclase and cyclic 3,5-nucleotide phosphodiesterase activities in muscles from stress-susceptible and control pigs.
Journal of Food Science 42: 111-112.

Ording, H. (1988):

Diagnosis of susceptibility of malignant hyperthermia in man.
Br. J. Anaesth. 60: 287-302.

Ording, H. and Shovgaard, L.T. (1987):

In vitro diagnosis of susceptibility to malignant hyperthermia: Comparison between dynamic and static halothane and caffeine tests:
Acta Anasthioloica Scandinavica 31: 458-461.

Ording, H. (1985):

Incidence of malignant hyperthermia in Denmark.
Anaesth. Analg. 64: 700-704.

Paasuke, R. and Brownell, A. (1986a):

Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia.
J. of the american medical association.
255: 729-771.

Paasuke, R. and Brownell, A. (1986b):

Amide local anaesthetics and malignant hyperthermia can.
Anaesth. Soc. J. 33: 126-129.

**Ranklev, E.; Henriksson, K.G.; Fletcher, R.; Germundsson, K.;
Oldfars, A. and Kalimo, H. (1986):**

Clinical and muscle biopsy finding in malignant
hyperthermia susceptibility.
Acta Neurologica Scandinavica 74: 452-459.

Ranklev, E.; Monti, M. and Fletcher, R. (1985):

Microcalorimetric studies in malignant hyperpyrexia
susceptible individuals.
Br. J. of anaesth. 57: 991-993.

Reyford, H.G.; Cordonnier, C. and Adnet, P.J. (1990):

The in vitro exposure of muscle strips from patients with
neuroleptic malignant syndrome (NMs) cannot be
correlated with the clinical features.
J. Neurol Sci, 98(suppl, 10): 527.

Richard, F. and Kaplan, M. (1992):

Malignant hyperthermia: ASA
Amerc. Society Anaesth. Esicologists 226: 1-7.

Richard, F. and Kaplan, M. (1991):

Malignant hyperthermia.
American society of anaesthesiologists, octoba; 231: 1-
7.

Rosenberg, H. (1988):

Managemet of patietns in whom trismus occurs following
succinylcholine.
Anaesthesiology 66: 654-655.

Rosenberg, H. and Reed, S. (1983):

In vitro contracture test for susceptibility to
malignant hyperthermia.
Anaesth. Analg. 62: 415-420.

Rosenberg, H.; Fisher, C.A.; Reed, S.B. and Addonizio, V.P. (1981):

Platelet aggregation in patients susceptible to malignant hyperthermia.
Anaesthesiology 55: 621-624.

Rutberg, H.; Hokanson, E.; Hall, G.M. and Jorfelat, L. (1987):

Effects of graded exercise on leg exchange of energy substrates in malignant hyperthermia susceptible subjects.
Anaesthesiology 67(in press).

Schwartz, L.; Rockoff, M. and Koka, B. (1984):

Masseter spasm with anaesthesia: Incidence and complication. 61: 772-775.

Schulman, M.; Braverman, B.; Ivankovich, A.D. and Gronert, G.A. (1981):

Sevoflurane triggers malignant hyperthermia in swine.
Anaesthesiology 54: 259-260.

Seay, A.R. and Ziter, F.A. (1978):

Malignant hyperpyrexia in a patient with Schwartz-Jampel syndrome.
Journal of Pediatrics 93: 83-84.

Sewell, K.; Flowerdew, R.M.M. and Bromberger, P. (1980):

Severe muscular rigidity at birth : malignant hyperthermia syndrome.
Can. Anaesth. Soci. J.; 27: 279-282.

Shuaib, A.; Paasuke, R.T. and brownell, A.K.W. (1987):

Central core disease. A reappraisal of its clinical features and new management recommendation Medicine (Baltimore); 66: 389-390.

Solomons., C.C. and Masson, N.C. (1984):

Platelet model for halothane-induced effects on nucleotide metabolism applied to malignant hyperthermia.
Acta Anaesthesiologica Scandinavica; 28: 185-190.

Sporn, P. (1981):

Maligne Hyperthermie. Ergebnisse Von
Familienuntersuchungen in osterreich.
Wiener Klinische Wochenschrift; 93(suppl. 132): 3-28.

Smitt, C. and Bush, G. (1985):

Anaesthesia and progressive muscular dystrophy.
Br. J. Anaesth. 57: 1113-1118.

Stanec, A. and Stefano, G. (1984):

Cyclic AMP in normal and malignant hyperpyrexia
susceptible individuals following exercise.
Br. J. of Anaesthesia; 56: 1243-1245.

**Taylor, C.A.; Lovrien, R.; Schanus, E.; Schendel, F. and
Kreul, J.F. (1981):**

Erythrocyte abnormalities in survivors of malignant
hyperthermia.
Anaesth and Analg. 60: 278-279.

Thach, B.T. (1986):

Sudden infant death syndrome.
New England Journal of Medicine 315: 126-128.

Traynorm, C.A.; VanDyke, R.A. and Gronert, G.A. (1983):

Phosphorylase ratio and susceptibility to malignant
hyperthermia.
Anaesth and Analg. 62: 324-326.

**Vanderspek, A.F.; Fang, W.V.; Asthon-Miller, J.A.; Stohler,
C.S.; Carlson, D.S. and Schark, M.A. (1987):**

The effects of succinylcholine on mouth opening.
Anaesthesiology 67: 459-495.

Vaughn, J.; Casson, H. and Hirshman, C. (1983):

Anaesthetic management of a child with asthma and
presumed susceptibility to malignant hyperthermia case
report.
Anaesthesiology 58: 283-285.

**Verburg, M.P.; Britt, B.A.; Oerlemans, F.T.J.J.; Scott, B.;
Van Egmund, J. and DeBruijn, C.H.M.M. (1986):**

Comparison of metabolites in skeletal muscle biopsies
from normal humans and those susceptible to malignant
hyperthermia.
Anaesthesiology 65: 654-657.

Viby-Mogensen, J. (1982):

Clinical assessment of neuromuscular transmission.
Br. J. Anaesth.; 54: 209-223.

**Walsh, M.P.; Brownell, A.K.W.; Littman, V. and Paasuke, R.T.
(1986):**

Electrophoresis of muscle proteins is not a method for
diagnosis of malignant hyperthermia susceptibility.
Anaesthesiology; 64: 473-479.

Waterman, P.M.; Albin, M.S. and Smith, R.B. (1980):

Malignant hyperthermia: A case report.
Anaesthesia and analgesia, 59: 220-221.

Waser, P.G. (1970):

On receptors in the postsynaptic membrans of the mator
end plate. Ciba foundation symposium on molecular
properties of drug receptors P.59. Ed. Porter, R. and
O'Connor.
M.London: J. and A. Churchill.

Whistler, T.; Isaacs, H. and Badenhorst, M. (1986):

No abnormal low molecular weight proteins identifeid in
human malignant hyperthermic muscle.
A naesthesiology; 64: 795-797.

Whittaker, M. and Britten, J.J. (1981):

Malignant hyperthermia and the fluoride-resistant gene.
Br. J. Anaesth; 53: 241-244.

Whittaker, M.; Spencer, R. and Searle, J. (1977):

Plasma chollinesterase and malignant hyperthermia.
Br. J. of Anaesth.; 49: 393.

Willner, J.H.; Cerri, C.G. and Wood, D.S. (1981):

High skeletal muscle adenylate cyclase in malignant hyperthermia.
Journal of Clinical Investigation 68:1119-1124.

Willner, J.H.; Wood, D.S.; Cerri, C.C. and Britt, B. (1980):

Increased myophosphorylase a in malignant hyperthermia.
New England, J. of Medicine 303: 138-140.

Williams, A. (1982):

Malignant hyperpyrexia?
Anaesthesia 37: 95-96.

Zsigmond, E.K.; Penner, J. and Kothary, S.P. (1978):

Normal erythrocyte fragility and abnormal platelet aggregation in malignant hyperthermia family: a pilot study.
In: Aldrete J.A.; Britt, B.A.; eds. Second international symposium on malignant hyperthermia.
New-York: Grune and strattor; 213-219.